Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Next Previous
Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lebrikizumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms LAVOLTA II
  • Sponsors Chugai Pharmaceutical; Roche

Most Recent Events

  • 17 Jul 2026 Actual primary completion date changed from 2 Jan 2017 to 28 Dec 2016.
  • 27 Feb 2023 Results from two studies ( LAVOLTA I(NCT01867125) n=721 and LAVOLTA II NCT01868061 ) assessing effects of LEB on inflammatory biomarkers in patients with asthma presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
  • 14 Nov 2022 Results of pooled analysis assessing the safety analysis of lebrikizumab during the 52-week placebo-controlled period of LAVOLTA I, LAVOLTA II, and ACOUSTICS studies, presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top